Health Condition 1: K858- Other acute pancreatitis
Conditions
Interventions
Intervention1: Standard therapy and Oral Rifaximin: Standard therapy and Oral Rifaximin( 550 mg BD) for 14 days
Control Intervention1: Standard Therapy: Standard therapy for sever acute pancreatitis
Sponsors
Department of gastroenterology and heaptology
Eligibility
Inclusion criteria
Inclusion criteria: Patients with a diagnosis of Predicted acute pancreatitis as per Atlanta classification presenting within seven days of pain onset Patients with a diagnosis of Predicted acute pancreatitis as per Atlanta classification presenting within seven days of pain onset Age >18 years With one of the following: 1.Predicted Severe acute pancreatitis indicated by 3 or more points according to Imrie score 2.Atlanta classifification 3.and/or CECT Abdomen findings of Balthazar grade D or E
Exclusion criteria
Exclusion criteria: 1.Previous history of allergy to Rifaximin 2.Patient with pancreatic malignancy 3.Postoperative pancreatitis after pancreatic surgery Bacteriologically proved infected necrosis at the time of randomization
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Development of infection of pancreatic necrosis documented by : â?¢Presence of gas on CECT or â?¢by positive culture from fine needle aspiration(FNA) in peri-pancreatic collection or â?¢Clinical deterioration or fever(38.5oC or 100.3oF) in absence of other explainable cause of infection (ie Pulmonary, UTI or Line infections) 2. Mortality Timepoint: 1.Time of discharge 2.till 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Duration of ICU or Hospital stay 2.Development of organ failure Timepoint: 1. At discharge | — |
Countries
India
Contacts
Public ContactPreetam Nath
Kalinga institute of medical sciences
Outcome results
None listed